Table 1.
Baseline characteristics of the study sample
| Characteristic | All patients (n = 45) |
|---|---|
| Age, years | 68.0 ± 7.80 |
| Gender | |
| Male | 36 (80.0) |
| Female | 9 (20.0) |
| Body mass index, kg/m2 | 23.1 ± 2.83 |
| FEV1/FVC, % | 69.1 ± 10.7 |
| FEV1, L | 2.26 ± 0.63 |
| FEV1, % | 83.3 ± 17.1 |
| Smoking status | |
| Current smoker | 12 (26.7) |
| Former smoker | 20 (44.4) |
| Never‐smoker | 13 (28.9) |
| Pack‐years of smoking | 36.8 ± 18.4 |
| Tumor size (cm) | 3.12 ± 2.24 |
| SUVmax | 8.08 ± 4.28 |
| Status of regional lymph nodes | |
| 0 | 34 (75.6) |
| 1 | 5 (11.1) |
| 2 | 6 (13.3) |
| Lung cancer stage | |
| I | 29 (64.4) |
| II | 7 (15.6) |
| III | 9 (20.0) |
| Histology | |
| Adenocarcinoma | 26 (57.8) |
| Squamous cell | 18 (40.0) |
| NSCLC, NOS | 1 (2.2) |
| Total emphysema scores | 1.21 ± 2.04 |
| Comorbid disease | |
| COPD | 23 (51.1) |
| Hypertension | 20 (44.4) |
| Diabetes | 9 (20.0) |
| Cardiovascular disease | 2 (4.4) |
| ILD | 2 (4.4) |
Values are presented as mean ± standard deviation or N (%).
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; ILD, interstitial lung disease; NOS, not otherwise specified; NSCLC, non‐small cell lung cancer; SUVmax, maximum standardized uptake value.